Sorry, you need to enable JavaScript to visit this website.

Key Pipeline Milestones

Download Report

Anticipated Regulatory Decisions

ABRYSVO (EU)

RSV infection (18-59 years)

milestone_check_1.svg

BRAFTOVI

1L BRAFm mCRC (PFS)

milestone_dash.svg

TALZENNA + XTANDI

mCRPC all-comers

milestone_check_2.svg
Anticipated Phase 3 Readouts

ELREXFIO

DCE multiple myeloma

milestone_dash.svg

HYMPAVZI

Hemophilia A or B with inhibitors

milestone_check_1.svg

Inclacumab

Sickle cell disease

milestone_check_2.svg

PADCEV

MIBC

milestone_check_1.svg

TUKYSA

HER2+ BC

milestone_check_1.svg

Vepdegestrant

2L ER+ mBC

milestone_check_1.svg
Potential Pivotal Program Starts
1H 2025

Sigvotatug vedotin (SV)

1L PD-L1-High NSCLC

milestone_check_1.svg
2H 2025

Danuglipron

Chronic weight management

milestone_check_2.svg

KAT6i

2L mBC

milestone_check_1.svg

NURTEC

Menstrual migraine

milestone_check_1.svg

PCV 25-valent

Pneumococcal infection (adult)

milestone_check_1.svg

PDL1V ADC

1L mHNSCC

milestone_check_1.svg

PDL1V ADC

2L+ NSCLC

milestone_check_2.svg

Ponsegromab

Cancer cachexia

milestone_asterisk.svg

milestone_check_1.svgcompleted

milestone_check_2.svgcompleted; didn’t meet primary endpoint OR development discontinued/no longer planned

milestone_dash.svgnow anticipated after YE 2025

milestone_asterisk.svgOpen for recruitment